DOCSLIB.ORG

Federal Register/Vol. 83, No. 121/Friday, June 22, 2018/Notices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 83, No. 121/Friday, June 22, 2018/Notices Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29127 Enhancement Award; 93.936, NIH Acquired (HHS Reference No. E–619–2013–0–US– within fifteen (15) days from the date of Immunodeficiency Syndrome Research Loan 01); this published notice, the National Repayment Program; 93.187, Undergraduate 2. PCT Application No. PCT/US2014/ Institute of Dental and Craniofacial Scholarship Program for Individuals from 058613, filed October 1, 2014 and Research receives written evidence and Disadvantaged Backgrounds, National entitled ‘‘Methods of Modulating Institutes of Health, HHS) argument that establishes that the grant Erythropoiesis with Arginine of the license would not be consistent Dated: June 19, 2018. Vasopressin Receptor 1B Molecules’’ with the requirements of 35 U.S.C. 209 Natasha M. Copeland, (HHS Reference No. E–619–2013–0– and 37 CFR part 404. PCT–02); In response to this Notice, the public Program Analyst, Office of Federal Advisory 3. U.S. Patent Application No. 15/ Committee Policy. may file comments or objections. 022,531, filed March 16, 2016 and [FR Doc. 2018–13419 Filed 6–21–18; 8:45 am] Comments and objections, other than entitled ‘‘Methods of Modulating those in the form of a license BILLING CODE 4140–01–P Erythropoiesis with Arginine application, will not be treated Vasopressin Receptor 1B Molecules’’ confidentially, and may be made (HHS Reference No. E–619–2013–0–US– DEPARTMENT OF HEALTH AND publicly available. 03); HUMAN SERVICES License applications submitted in The patent rights in these inventions response to this Notice will be National Institutes of Health have been assigned and/or exclusively presumed to contain business licensed to the government of the confidential information and any release Prospective Grant of an Exclusive United States of America. of information in these license Patent License: Methods of Modulating The prospective exclusive license applications will be made only as Erythropoiesis With Arginine territory may be the United States and required and upon a request under the Vasopressin Receptor 1B Molecules the field of use may be limited to ‘‘Use Freedom of Information Act, 5 U.S.C. of arginine vasopressin receptor 1B 552. AGENCY: National Institutes of Health, agonists to treat anemia caused by (i) HHS. chronic renal failure on dialysis, (ii) Dated: June 19, 2018. David W. Bradley, ACTION: Notice. receiving myelosuppressive chemotherapy, or (iii) lacking Director, Office of Technology Transfer and SUMMARY: The National Institute of antidiuretic hormone.’’ Innovation Access, National Institute of Dental and Craniofacial Research, an The subject technology is a method of Dental and Craniofacial Research, National institute of the National Institutes of using arginine vasopressin receptor 1B Institutes of Health. Health, Department of Health and (AVPR1B) agonists to increase the [FR Doc. 2018–13443 Filed 6–21–18; 8:45 am] Human Services, is contemplating the number of red blood cells to treat BILLING CODE 4140–01–P grant of an Exclusive Patent License to anemia. The inventors discovered that practice the inventions embodied in the hematopoietic stem cells express Patent Applications listed in the AVPR1B receptor, and these receptors DEPARTMENT OF HEALTH AND Supplementary Information section of play a key role in promoting HUMAN SERVICES hematopoietic stem and progenitor cell this notice to ERYTHRYx Therapeutics, National Institutes of Health located in Los Angeles, California. proliferation. The number of red blood DATES: Only written comments and/or cells and their precursors significantly Government-Owned Inventions; applications for a license which are increased on day 2 following Availability for Licensing received by the Office of Technology vasopressin administration, an onset AGENCY: National Institutes of Health, Transfer and Innovation Access, time much faster than erythropoietin HHS. National Institute of Dental and (EPO), which is commonly used to Craniofacial Research on or before July stimulate red blood cell production for ACTION: Notice. 9, 2018 will be considered. anemia treatment. EPO takes about a week to manifest its clinical effects. The SUMMARY: The invention listed below is ADDRESSES: Requests for copies of the AVPR1B agonists can be used to owned by an agency of the U.S. patent application, inquiries, and jumpstart the hematopoietic system and Government and is available for comments relating to the contemplated erythropoietin can be used to sustain licensing to achieve expeditious an Exclusive Patent License should be the effect. commercialization of results of directed to: Yun Mei, Technology The subject technology is a federally-funded research and Transfer and Patent Specialist, Office of repurposing of an existing drug, development. Foreign patent Technology Transfer and Innovation vasopressin, an AVPR1B agonist, also applications are filed on selected Access, National Institute of Dental and called antidiuretic hormone. It is a nine- inventions to extend market coverage Craniofacial Research, National amino acid peptide secreted from the for companies and may also be available Institutes of Health, BLDG 1 DEM, posterior pituitary and used to treat for licensing. RM667, 6701 Democracy Blvd., patients with central diabetes insipidus, FOR FURTHER INFORMATION CONTACT: Dr. Bethesda, MD 20817; Telephone: (301) an uncommon disorder that causes an Barry Buchbinder, 240–627–3678; 827–4639; Facsimile: (301) 496–1005; imbalance of water in the body. This [email protected]. Licensing Email: [email protected]. imbalance leads to excretion of large information and copies of the U.S. SUPPLEMENTARY INFORMATION: amount of urine (polyuria) and intense patent application listed below may be thirst even after drinking fluids obtained by communicating with the Intellectual Property (polydipsia). indicated licensing contact at the 1. U.S. Provisional Patent Application This notice is made in accordance Technology Transfer and Intellectual No. 61/885,258, filed October 1, 2013 with 35 U.S.C. 209 and 37 CFR part 404. Property Office, National Institute of and entitled ‘‘Methods of Modulating The prospective exclusive license will Allergy and Infectious Diseases, 5601 Erythropoiesis with Arginine be royalty bearing, and the prospective Fishers Lane, Rockville, MD 20852; tel. Vasopressin Receptor 1B Molecules’’ exclusive license may be granted unless 301–496–2644. A signed Confidential VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1 daltland on DSKBBV9HB2PROD with NOTICES.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Effects of Chronic Psychosocial Stress on HPA Axis Functionality in Male C57BL/6 Mice and the Impact of Trait Anxiety on the Individual Stress Vulnerability
    Effects of chronic psychosocial stress on HPA axis functionality in male C57BL/6 mice and the impact of trait anxiety on the individual stress vulnerability DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR. RER. NAT.) DER FAKULTÄT FÜR BIOLOGIE UND VORKLINISCHE MEDIZIN DER UNIVERSITÄT REGENSBURG vorgelegt von Andrea Monika Füchsl aus Straubing im Jahr 2013 Das Promotionsgesuch wurde eingereicht am: 04.10.2013 Die Arbeit wurde angeleitet von: Prof. Dr. rer. nat. Inga D. Neumann Unterschrift: DISSERTATION Durchgeführt am Institut für Zoologie der Universität Regensburg TABLE OF CONTENTS I Table of Contents Chapter 1 – Introduction 1 Stress ...................................................................................................... 1 1.1 The Stress System ..................................................................................... 1 1.1.2 Sympathetic nervous system (SNS) ..................................................... 2 1.2.2 Hypothalamic-Pituitary-Adrenal (HPA) axis .......................................... 4 1.2 Acute vs. chronic/repeated stress ............................................................. 13 1.3 Psychosocial stress .................................................................................. 18 2 GC Signalling ....................................................................................... 20 2.1 Corticosteroid availability .......................................................................... 20 2.2 Corticosteroid receptor types in the brain .................................................
    [Show full text]
  • 1 Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist Table S1. Kinase Panel Screening Performe
    Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Kärrman Mårdh C. JPET #221358 Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist David Nicholls, Katherine Wiley, Ian Dainty, Fraser MacIntosh, Caroline Phillips, Alasdair Gaw, Carina Kärrman Mårdh. The Journal of Pharmacology and Experimental Therapeutics Table S1. Kinase panel screening performed at Dundee University ATP Inhibition Target (μM) (%) AMP-activated Protein Kinase 50 19 Cyclin Dependent Kinase 2:Cyclin A 20 18 Checkpoint Kinase I 20 10 Casein Kinase 1 20 -6 Casein Kinase 2 5 4 Lymphocyte-Specific Protein Tyrosine Kinase 50 -5 Mitogen Activated Protein Kinase 1 50 13 MAPK Activated Protein Kinase-1a 50 -3 MAPK Activated Protein Kinase-2 20 13 Mitogen Activated Protein Kinase Kinase 1 5 21 Protein Kinase, cAMP-dependent, catalytic, alpha 5 -71 v-akt murine thymoma viral oncogene homolog 1 5 19 Protein Kinase C alpha 20 9 p38 Regulated Activated Kinase 20 7 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A 50 15 Glycogen Synthase Kinase-3 beta 5 12 Mitogen Activated Protein Kinase 8 20 9 Mitogen and Stress Activated Protein Kinase 1 20 8 P70S6 Kinase 20 22 Phospho B Kinase 20 4 3-Phosphoinositide Dependent Protein Kinase-1 20 10 Rho Associated, Coiled Coil Containing Protein Kinase 2 20 2 Stress Activated Protein Kinase 2a 50 4 Stress Activated Protein Kinase 2b 20 17 Serum and Glucocorticoid Regulated Kinase? 20 11 1 Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Kärrman Mårdh C.
    [Show full text]
  • Vasopressin and Oxytocin in Control of the Cardiovascular System
    Send Orders of Reprints at [email protected] 218 Current Neuropharmacology, 2013, 11, 218-230 Vasopressin and Oxytocin in Control of the Cardiovascular System Nina Japundi-igon* Professor of Basic and Clinical Pharmacology and Toxicology, University of Belgrade School of Medicine, Institute of Pharmacology, Clinical Pharmacology and Toxicology, Dr Subotica 1, Belgrade, Republic of Serbia Abstract: Vasopressin (VP) and oxytocin (OT) are mainly synthesized in the magnocellular neurons of the paraventricular (PVN) and supraoptic nucleus (SON) of the hypothalamus. Axons from the magnocellular part of the PVN and SON project to neurohypophysis where VP and OT are released in blood to act like hormones. Axons from the parvocellular part of PVN project to extra-hypothalamic brain areas (median eminence, limbic system, brainstem and spinal cord) where VP and OT act like neurotransmitters/modulators. VP and OT act in complementary manner in cardiovascular control, both as hormones and neurotransmitters. While VP conserves water and increases circulating blood volume, OT eliminates sodium. Hyperactivity of VP neurons and quiescence of OT neurons in PVN underlie osmotic adjustment to pregnancy. In most vascular beds VP is a potent vasoconstrictor, more potent than OT, except in the umbilical artery at term. The vasoconstriction by VP and OT is mediated via V1aR. In some vascular beds, i.e. the lungs and the brain, VP and OT produce NO dependent vasodilatation. Peripherally, VP has been found to enhance the sensitivity of the baro-receptor while centrally, VP and OT increase sympathetic outflow, suppresse baro-receptor reflex and enhance respiration. Whilst VP is an important mediator of stress that triggers ACTH release, OT exhibits anti-stress properties.
    [Show full text]
  • Amy C. Allen Dissertation
    Food, Friends and Foes: Estrogens and Social Behaviour in Mice by Amy Elizabeth Clipperton Allen A Thesis presented to The University of Guelph In partial fulfilment of requirements for the degree of Doctor of Philosophy in Psychology + Neuroscience Guelph, Ontario, Canada © Amy E. Clipperton-Allen, December, 2011 ABSTRACT FOOD, FRIENDS AND FOES: ESTROGENS AND SOCIAL BEHAVIOUR IN MICE Amy Elizabeth Clipperton Allen Advisor: University of Guelph, 2011 Professor Elena Choleris This thesis investigates estrogens' modulation of three aspects of social cognition (aggression and agonistic behaviour, social learning, and social recognition). Sex-typical agonistic behaviour (males: overt attacks, females: more subtle dominance behaviours) was increased in gonadectomized mice by estrogen receptor alpha (ERα) agonist 1,3,5-tris(4- hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), while non-overt agonistic behaviour was increased in male and female gonadally intact mice by ERβ agonist 7-Bromo-2-(4- hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY-200070). Estrogens also affected the social transmission of food preferences (STFP). Acute estrogen and ERβ agonists WAY-200070 and 2,3-bis(4-hydroxyphenyl)propionitrile (DPN) prolonged the preference for the demonstrated food when administered pre-acquisition, likely by affecting motivation or the nature of the social interaction, while acute PPT blocked the STFP. All mice receiving any of the three treatments chronically showed a prolonged demonstrated food preference, suggesting a loss of ER specificity. Individual differences in social recognition may relate to increased oxytocin (OT) and vasopressin (AVP) mRNA, and ERα and ERβ gene activation, in the medial preoptic area, and decreased mRNA for ERs, OT receptor (OTR), AVP and AVP receptors 1a and 1b in the lateral amygdala.
    [Show full text]
  • Mrna Expression in Human Leiomyoma and Eker Rats As Measured by Microarray Analysis
    Table 3S: mRNA Expression in Human Leiomyoma and Eker Rats as Measured by Microarray Analysis Human_avg Rat_avg_ PENG_ Entrez. Human_ log2_ log2_ RAPAMYCIN Gene.Symbol Gene.ID Gene Description avg_tstat Human_FDR foldChange Rat_avg_tstat Rat_FDR foldChange _DN A1BG 1 alpha-1-B glycoprotein 4.982 9.52E-05 0.68 -0.8346 0.4639 -0.38 A1CF 29974 APOBEC1 complementation factor -0.08024 0.9541 -0.02 0.9141 0.421 0.10 A2BP1 54715 ataxin 2-binding protein 1 2.811 0.01093 0.65 0.07114 0.954 -0.01 A2LD1 87769 AIG2-like domain 1 -0.3033 0.8056 -0.09 -3.365 0.005704 -0.42 A2M 2 alpha-2-macroglobulin -0.8113 0.4691 -0.03 6.02 0 1.75 A4GALT 53947 alpha 1,4-galactosyltransferase 0.4383 0.7128 0.11 6.304 0 2.30 AACS 65985 acetoacetyl-CoA synthetase 0.3595 0.7664 0.03 3.534 0.00388 0.38 AADAC 13 arylacetamide deacetylase (esterase) 0.569 0.6216 0.16 0.005588 0.9968 0.00 AADAT 51166 aminoadipate aminotransferase -0.9577 0.3876 -0.11 0.8123 0.4752 0.24 AAK1 22848 AP2 associated kinase 1 -1.261 0.2505 -0.25 0.8232 0.4689 0.12 AAMP 14 angio-associated, migratory cell protein 0.873 0.4351 0.07 1.656 0.1476 0.06 AANAT 15 arylalkylamine N-acetyltransferase -0.3998 0.7394 -0.08 0.8486 0.456 0.18 AARS 16 alanyl-tRNA synthetase 5.517 0 0.34 8.616 0 0.69 AARS2 57505 alanyl-tRNA synthetase 2, mitochondrial (putative) 1.701 0.1158 0.35 0.5011 0.6622 0.07 AARSD1 80755 alanyl-tRNA synthetase domain containing 1 4.403 9.52E-05 0.52 1.279 0.2609 0.13 AASDH 132949 aminoadipate-semialdehyde dehydrogenase -0.8921 0.4247 -0.12 -2.564 0.02993 -0.32 AASDHPPT 60496 aminoadipate-semialdehyde
    [Show full text]
  • Characterisation of L-Cell Secretory Mechanisms and Colonic
    Characterisation of L -cell secretory mechanisms and colonic enteroendocrine cell subpopulations Lawrence Billing Downing College, Cambridge This dissertation is submitted for the degree of Doctor of Philosophy September 2018 Abstract Enteroendocrine cells (EECs) are chemosensitive cells of the gastrointestinal epithelium that exert a wide range of physiological effects via production and secretion of hormones in response to ingested nutrients, bacterial metabolites and systemic signals. Glucagon-like peptide-1 (GLP-1) is one such hormone secreted from so-called L-cells found in both the small and large intestines. GLP-1 exerts an anorexigenic effect and together with glucose- dependent insulinotropic polypeptide (GIP), restores postprandial normoglycaemia through the incretin effect. These effects are exploited by GLP-1 analogues in the treatment of type 2 diabetes. GLP-1 may also contribute to weight-loss and remission of type 2 diabetes following bariatric surgery which increases postprandial GLP-1 excursions. Here we investigated stimulus secretion coupling in L-cells. A novel 2D culture system from murine small intestinal organoids was established as an in vitro model. This was used to characterise synergistic stimulation of GLP-1 secretion in response to concomitant stimulation by bile acids through the Gs-protein coupled receptor GPBAR1 and free fatty acids through the Gq-coupled receptor FFAR1. Roughly half of colonic, but not small intestinal, L-cells co-produce the orexigenic peptide insulin-like peptide 5 (INSL5). This hitherto poorly examined subpopulation of L-cells was characterised through transcriptomic analysis, intracellular calcium imaging (using a novel GCaMP6F-based transgenic mouse model), LC/MS peptide quantification and 3D super resolution microscopy (3D-SIM).
    [Show full text]
  • RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT
    RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT Cat. no. 330231 PAMM-3009ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Mouse G Protein Coupled Receptors 384HT RT² Profiler™ PCR Array profiles the expression of a comprehensive panel of 370 genes encoding the most important G Protein Coupled Receptors (GPCR). GPCR regulate a number of normal biological processes and play roles in the pathophysiology of many diseases upon dysregulation of their downstream signal transduction activities. As a result, they represent 30 percent of the targets for all current drug development. Developing drug screening assays requires a survey of which GPCR the chosen cell-based model system expresses, to determine not only the expression of the target GPCR, but also related GPCR to assess off-target side effects. Expression of other unrelated GPCR (even orphan receptors whose ligand are unknown) may also correlate with off-target side effects. The ligands that bind and activate the receptors on this array include neurotransmitters and neuropeptides, hormones, chemokines and cytokines, lipid signaling molecules, light-sensitive compounds, and odorants and pheromones. The normal biological processes regulated by GPCR include, but are not limited to, behavioral and mood regulation (serotonin, dopamine, GABA, glutamate, and other neurotransmitter receptors), autonomic (sympathetic and parasympathetic) nervous system transmission (blood pressure, heart rate, and digestive processes via hormone receptors), inflammation and immune system regulation (chemokine receptors, histamine receptors), vision (opsins like rhodopsin), and smell (olfactory receptors for odorants and vomeronasal receptors for pheromones).
    [Show full text]
  • Human Recombinant V1B Vasopressin Receptor Stable Cell
    Human V1B Receptor Membrane Preparation Technical Manual No. TM0497 Version 10132010 I Introduction ….……………………………………………………………………………. 1 II Background ………..………………………………………………………………………. 1 III Representative Data.……………………………………………………………………… 2 IV Brief Competition Binding Protocol ……………………………………………………… 3 V References ………………………………………………………………………………. 3 I. Introduction Catalog Number: M00401 Cell Line: CHO-K1/V1B Expressed Gene: GenBank Accession Number NM_000706; no expressed tags Alternate Names: V1BR, arginine vasopressin receptor 1B Host Cell: CHO-K1 Quantity: 1 vial (1 ml per vial) Protein Concentration: 2 mg/ml Buffer: 50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2 and 0.2% BSA, pH7.4 Application: Binding assay for V1B receptor Storage: Store at -80°C II. Background: The antidiuretic hormone arginine vasopressin (AVP) receptors are G protein-coupled receptors which consists of at least three types: V1A (vascular/hepatic) and V1B (anterior pituitary) receptors, which act through phosphatidylinositol hydrolysis to mobilize intracellular Ca2+, and V2 (kidney) receptor, which is coupled to adenylate cyclase. V1B receptors are expressed in anterior pituitary where they mediate the release of ACTH. Its peripheral actions, such as antidiuresis, contraction of vascular smooth muscle, and stimulation of hepatic glycogenolysis are well characterized. -1- III. Representative Data Saturation Bindinig for V1B Receptor 1.2 Total Binding 1.0 Specific Binding NSB 0.8 0.6 B = 1.31 pmol/mg protein 0.4 max K = 0.28 nM pmol/mg protein pmol/mg d 0.2 0.0 0.00 0.25 0.50 0.75 1.00 [3H](Arg8)-Vasopressin (nM) Figure 1 10 μg of membranes prepared from CHO-K1 cells stably expressing V1B receptors were incubated with indicated concentrations of [3H](Arg8)Vasopressin in the absence (total binding) or presence of 1000-fold excess unlabeled (Arg8)Vasopressin (nonspecific binding, NSB).
    [Show full text]
  • Oxytocin and Vasopressin Receptor Variants As a Window Onto
    bioRxiv preprint doi: https://doi.org/10.1101/460584; this version posted November 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Oxytocin and Vasopressin Receptor variants as a 2 window onto the evolution of human prosociality 1,2,3,+ 1,2,+ 1,2,4,* 3 Constantina Theofanopoulou , Alejandro Andirko´ , and Cedric Boeckx 1 4 Section of General Linguistics, Universitat de Barcelona 2 5 Universitat de Barcelona Institute for Complex Systems 3 6 Laboratory of Neurogenetics of Language, Rockefeller University 4 7 ICREA * 8 [email protected] + 9 these authors contributed equally to this work 10 ABSTRACT Modern humans’ lifestyle strongly depends on complex social skills like empathy, tolerance and cooperation. Variation in the oxytocin receptor (OXTR) and the arginine-vasopressin receptors (AVPR1A, AVPR1B genes) has been widely associated with diverse facets of social cognition, but the extent to which these variants may have contributed to the evolution of human prosociality remains to be elucidated. In this study, we compared the OXTR, AVPR1A and AVPR1B DNA sequences of modern humans to those of our closest extinct and extant relatives, and then clustered the variants we identified based on their distribution in the species studied. This clustering, along with the functional importance retrieved for each variant and their frequency in different modern-human populations, is then used to determine if any of the OXTR, AVPR1A and AVPR1B-variants 11 might have had an impact at different evolutionary stages.
    [Show full text]
  • Supplementary Information For
    Supplementary Information for Multimodal gradients across mouse cortex Ben D. Fulcher, John D. Murray, Valerio Zerbi, and Xiao-Jing Wang Ben D. Fulcher and Xiao-Jing Wang. E-mails: [email protected] and [email protected] This PDF file includes: Supplementary text Figs. S1 to S9 Tables S1 to S2 References for SI reference citations Ben D. Fulcher, John D. Murray, Valerio Zerbi, and Xiao-Jing Wang 1 of 20 www.pnas.org/cgi/doi/10.1073/pnas.1814144116 Supporting Information Text Data Cortical parcellation. The 40 mouse cortical areas analyzed here are from the Allen Reference Atlas (ARA) (1), and labeled (where possible) according to the following grouping from Harris et al. (2): Somatomotor: ‘MOp’ (Primary motor area), ‘SSp-n’ (Primary somatosensory area, nose), ‘SSp-bfd’ (Primary somatosensory area, barrel field), ‘SSp-ll’ (Primary somatosensory area, lower limb), ‘SSp-m’ (Primary somatosensory area, mouth), ‘SSp-ul’ (Primary somatosensory area, upper limb), ‘SSp-tr’ (Primary somatosensory area, trunk), ‘SSp-un’ (Primary somatosensory area, unassigned), ‘SSs’ (Supplemental somatosensory area). Medial: ‘PTLp’ (Posterior parietal association areas), ‘VISam’ (Anteromedial visual area), ‘VISpm’ (Posteromedial visual area), ‘RSPagl’ (Retrosplenial area, lateral agranular part), ‘RSPd’ (Retrosplenial area, dorsal part), ‘RSPv’ (Retrosplenial area, ventral part). Temporal: ‘AUDd’ (Dorsal auditory area), ‘AUDp’ (Primary auditory area), ‘AUDpo’ (Posterior auditory area), ‘AUDv’ (Ventral auditory area), ‘TEa’ (Temporal association areas), ‘PERI’ (Perirhinal area), ‘ECT’ (Ectorhinal area). Visual: ‘VISal’ (Anterolateral visual area), ‘VISl’ (Lateral visual area), ‘VISp’ (Primary visual area), ‘VISpl’ (Posterolateral visual area). Anterolateral: ‘GU’ (Gustatory areas), ‘VISC’ (Visceral area), ‘AId’ (Agranular insular area, dorsal part), ‘AIp’ (Agranular insular area, posterior part), ‘AIv’ (Agranular insular area, ventral part).
    [Show full text]
  • Role of the Vasopressin 1B Receptor in Rodent Aggressive Behavior and Synaptic Plasticity in Hippocampal Area CA2
    Molecular Psychiatry (2015) 20, 490–499 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE Role of the vasopressin 1b receptor in rodent aggressive behavior and synaptic plasticity in hippocampal area CA2 JH Pagani1,3, M Zhao2,3, Z Cui1,3, SK Williams Avram1, DA Caruana2,4, SM Dudek2 and WS Young1 The vasopressin 1b receptor (Avpr1b) is critical for social memory and social aggression in rodents, yet little is known about its specific roles in these behaviors. Some clues to Avpr1b function can be gained from its profile of expression in the brain, which is largely limited to the pyramidal neurons of the CA2 region of the hippocampus, and from experiments showing that inactivation of the gene or antagonism of the receptor leads to a reduction in social aggression. Here we show that partial replacement of the Avpr1b through lentiviral delivery into the dorsal CA2 region restored the probability of socially motivated attack behavior in total Avpr1b knockout mice, without altering anxiety-like behaviors. To further explore the role of the Avpr1b in this hippocampal region, we examined the effects of Avpr1b agonists on pyramidal neurons in mouse and rat hippocampal slices. We found that selective Avpr1b agonists induced significant potentiation of excitatory synaptic responses in CA2, but not in CA1 or in slices from Avpr1b knockout mice. In a way that is mechanistically very similar to synaptic potentiation induced by oxytocin, Avpr1b agonist-induced potentiation of CA2 synapses relies on NMDA (N-methyl-D-aspartic acid) receptor activation, calcium and calcium/calmodulin- dependent protein kinase II activity, but not on cAMP-dependent protein kinase activity or presynaptic mechanisms.
    [Show full text]